CureVac N.V., Form 6-K, For the month of July 2024
Summary
A Form 6-K report of foreign private issuer CureVac N.V., Commission File Number 001-39446, for the month of July 2024, signed on July 3, 2024 by /s/ Alexander Zehnder, Chief Executive Officer. It reports that on July 3, 2024 the company issued a press release announcing that it and GSK plc have restructured their existing collaboration into a new licensing agreement, and a second press release announcing a strategic restructuring to focus resources on high-value mRNA projects in oncology and other select areas of substantial unmet medical need. The releases are attached as Exhibits 99.1 and 99.2, and the report, excluding the quoted statements of GSK's Chief Scientific Officer and the company's Chief Executive Officer, is incorporated by reference into the company's Registration Statement on Form F-3 (File No. 333-259613).
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Full text
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-39446 CureVac N.V. ( Exact Name of Registrant as Specified in Its Charter ) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨ On July 3, 2024, CureVac N.V. (the “Company”) issued a press release announcing that the Company and GSK plc have restructured their existing collaboration into a new licensing agreement. On July 3, 2024, the Company also issued a press release announcing a strategic restructuring to focus its resources on high-value mRNA projects in oncology and other select areas of substantial unmet medical need. The information included in this Form 6-K (including Exhibits 99.1 and 99.2, but excluding the statements of GSK’s Chief Scientific Officer and the Company’s Chief Executive Officer contained in Exhibit 99.1 hereto and excluding the statements of the Company’s Chief Executive Officer contained in Exhibit 99.2) is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-259613). SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CUREVAC N.V. By: | /s/ Alexander Zehnder Chief Executive Officer Date: July 3, 2024 EXHIBIT INDEX EXHIBIT NO. | DESCRIPTION 99.1 | GSK and CureVac to Restructure Collaboration into New Licensing Agreement 99.2 | CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
File and source
- File
- tm2418882d1_6k.htm.html
- Size
- 10,857 bytes
- SHA-256
- ecb1ca1555144d6dbb99021d28efc41ac1946512977c8ae5857e5290f1e2efb9
- Our copy
- tm2418882d1_6k.htm.html
- Original
- www.sec.gov